Login Register Cart 0
Generic placeholder image

Recent Advances in Drug Delivery and Formulation

Editor-in-Chief

ISSN (Print): 2667-3878
ISSN (Online): 2667-3886

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Review Article

Drug Delivery through Co-amorphous Solid Dispersions: A Comprehensive and Updated Review on Physicochemical Characteristics and Biological Potential

Author(s): Shailender Mohan and Abdul Hafeez*

Volume 19, Issue 4, 2025

Published on: 18 April, 2025

Page: [327 - 352] Pages: 26

DOI: 10.2174/0126673878351727250409094214

Price: $65

Abstract

New chemical entities with low aqueous solubility and permeability encounter significant challenges in formulation development. Low solubility is further accompanied by slow dissolution and poor bioavailability, which in turn leads to unpredictability in terms of both bioavailability and toxicity. Therefore, a significant amount of exertion is necessary to enhance solubility, dissolution, and eventually bioavailability. Additionally, to enhance the solubility properties and amorphous stability of BCS Class II medications and ultimately increase drug bioavailability, coamorphization has emerged as a promising strategy. Co-amorphous solid dispersions (CASD) are multi-component single-phase amorphous solid dispersions comprising two or more small molecules (usually known as co-formers) that might be a combination of drug-drug or drug-excipients. The selection of appropriate co-formers is critical, and the surface properties of co-amorphous formulations must be carefully evaluated, as they influence physical and chemical stability in addition to dissolution performance. Scaling up and processing co-amorphous formulations into the final dosage forms presents challenges that need to be addressed. This review will largely concentrate on the challenges, improvements, and innovations in physicochemical properties, biological characterization, and advancements of co-amorphous systems. This review will also furnish a comprehensive explanation of both established and emerging approaches utilized in the estimation of physicochemical attributes and characterization of CASD (in vitro and in vivo). Regarding CASD’s potential to improve patient outcomes and therapeutic efficacy, it has emerged as a viable approach for drug candidates posing the problems of solubility and bioavailability. This approach has also increased the physical stability of drugs.

Keywords: Co-amorphous solid dispersion, biological potential, co-former, physical stability, solubility improvement, bioavailability enhancement.

« Previous Next »
Graphical Abstract

[1]
Liu J, Grohganz H, Löbmann K, Rades T, Hempel NJ. Co-amorphous drug formulations in numbers: recent advances in co-amorphous drug formulations with focus on co-formability, molar ratio, preparation methods, physical stability, in vitro and in vivo performance, and new formulation strategies. Pharmaceutics 2021; 13(3): 389.
[http://dx.doi.org/10.3390/pharmaceutics13030389] [PMID: 33804159]
[2]
Jermain SV, Brough C, Williams RO III. Amorphous solid dispersions and nanocrystal technologies for poorly water-soluble drug delivery – An update. Int J Pharm 2018; 535(1-2): 379-92.
[http://dx.doi.org/10.1016/j.ijpharm.2017.10.051] [PMID: 29128423]
[3]
Bhujbal SV, Mitra B, Jain U, et al. Pharmaceutical amorphous solid dispersion: A review of manufacturing strategies. Acta Pharm Sin B 2021; 11(8): 2505-36.
[http://dx.doi.org/10.1016/j.apsb.2021.05.014] [PMID: 34522596]
[4]
Rocha B, de Morais LA, Viana MC, Carneiro G. Promising strategies for improving oral bioavailability of poor water-soluble drugs. Expert Opin Drug Discov 2023; 18(6): 615-27.
[http://dx.doi.org/10.1080/17460441.2023.2211801] [PMID: 37157841]
[5]
Ge Y, Huang B, Li L, et al. Structural transformation of unconventional-phase materials. ACS Nano 2023; 17(14): 12935-54.
[http://dx.doi.org/10.1021/acsnano.3c01922] [PMID: 37428980]
[6]
Singh R, Joshi V, Mehetre N, Sangamwar AT. Insights into co-amorphous systems in therapeutic drug delivery. Ther Deliv 2021; 12(3): 245-65.
[http://dx.doi.org/10.4155/tde-2020-0109] [PMID: 33745286]
[7]
Vullendula SKA, Nair AR, Yarlagadda DL, Navya Sree KS, Bhat K, Dengale SJ. Polymeric solid dispersion vs co-amorphous technology: A critical comparison. J Drug Deliv Sci Technol 2022; 78103980.
[http://dx.doi.org/10.1016/j.jddst.2022.103980]
[8]
Shi Q, Li F, Yeh S, et al. Recent advances in enhancement of dissolution and supersaturation of poorly water-soluble drug in amorphous pharmaceutical solids: A review. AAPS PharmSciTech 2021; 23(1): 16.
[http://dx.doi.org/10.1208/s12249-021-02137-0] [PMID: 34893936]
[9]
Yarlagadda DL, Sai Krishna Anand V, Nair AR, Navya Sree KS, Dengale SJ, Bhat K. Considerations for the selection of co-formers in the preparation of co-amorphous formulations. Int J Pharm 2021; 602120649.
[http://dx.doi.org/10.1016/j.ijpharm.2021.120649] [PMID: 33915186]
[10]
Shi Q, Moinuddin SM, Cai T. Advances in coamorphous drug delivery systems. Acta Pharm Sin B 2019; 9(1): 19-35.
[http://dx.doi.org/10.1016/j.apsb.2018.08.002] [PMID: 30766775]
[11]
Li B, Konecke S, Wegiel LA, Taylor LS, Edgar KJ. Both solubility and chemical stability of curcumin are enhanced by solid dispersion in cellulose derivative matrices. Carbohydr Polym 2013; 98(1): 1108-16.
[http://dx.doi.org/10.1016/j.carbpol.2013.07.017] [PMID: 23987452]
[12]
Wang R, Han J, Jiang A, et al. Involvement of metabolism-permeability in enhancing the oral bioavailability of curcumin in excipient-free solid dispersions co-formed with piperine. Int J Pharm 2019; 561: 9-18.
[http://dx.doi.org/10.1016/j.ijpharm.2019.02.027] [PMID: 30817985]
[13]
Okem A, Henstra C, Lambert M, Hayeshi R. A review of the pharmacodynamic effect of chemo-herbal drug combinations therapy for cancer treatment. Med Drug Discov 2023; 17100147.
[http://dx.doi.org/10.1016/j.medidd.2022.100147]
[14]
Wang H, Zhao P, Ma R, Jia J, Fu Q. Drug–drug co-amorphous systems: An emerging formulation strategy for poorly water-soluble drugs. Drug Discov Today 2024; 29(2): 103883.
[http://dx.doi.org/10.1016/j.drudis.2024.103883] [PMID: 38219970]
[15]
Berretta M, Dal Lago L, Tinazzi M, et al. Evaluation of concomitant use of anticancer drugs and herbal products: From interactions to synergic activity. Cancers 2022; 14(21): 5203.
[http://dx.doi.org/10.3390/cancers14215203] [PMID: 36358622]
[16]
Korhonen O, Pajula K, Laitinen R. Rational excipient selection for co-amorphous formulations. Expert Opin Drug Deliv 2017; 14(4): 551-69.
[http://dx.doi.org/10.1080/17425247.2016.1198770] [PMID: 27267873]
[17]
Ueda H, Muranushi N, Sakuma S, et al. A strategy for co-former selection to design stable co-amorphous formations based on physicochemical properties of non-steroidal inflammatory drugs. Pharm Res 2016; 33(4): 1018-29.
[http://dx.doi.org/10.1007/s11095-015-1848-2] [PMID: 26700604]
[18]
Hansen CM. Hansen Solubility Parameters. CRC Press 2007.
[http://dx.doi.org/10.1201/9781420006834]
[19]
Nistane J, Chen L, Lee Y, Lively R, Ramprasad R. Estimation of the Flory-Huggins interaction parameter of polymer-solvent mixtures using machine learning. MRS Commun 2022; 12(6): 1096-102.
[http://dx.doi.org/10.1557/s43579-022-00237-x]
[20]
Venkatram S, Kim C, Chandrasekaran A, Ramprasad R. Critical assessment of the hildebrand and hansen solubility parameters for polymers. J Chem Inf Model 2019; 59(10): 4188-94.
[http://dx.doi.org/10.1021/acs.jcim.9b00656] [PMID: 31545900]
[21]
Padmarajan R, Kalpathy SK. Estimation of Flory–Huggins interaction parameters and miscibility gaps in poly(sodium 4-styrenesulfonate) - water - 1,4-butanediol mixtures via linearized cloud point curve correlations. Fluid Phase Equilib 2024; 576113935.
[http://dx.doi.org/10.1016/j.fluid.2023.113935]
[22]
Aher AA, Shaikh KS, Chaudhari PD. Stability of co-amorphous solid dispersions: Physical and chemical aspects. J Struct Chem 2023; 64(4): 686-738.
[http://dx.doi.org/10.1134/S0022476623040157]
[23]
Liu J, Grohganz H, Rades T. Influence of polymer addition on the amorphization, dissolution and physical stability of co-amorphous systems. Int J Pharm 2020; 588119768.
[http://dx.doi.org/10.1016/j.ijpharm.2020.119768] [PMID: 32798592]
[24]
Sihorkar V, Dürig T. The role of polymers and excipients in developing amorphous solid dispersions: An industrial perspective. Drug Delivery Aspects. Elsevier 2020; pp. 79-113.
[http://dx.doi.org/10.1016/B978-0-12-821222-6.00005-1]
[25]
Baghel S, Cathcart H, O’Reilly NJ. Polymeric amorphous solid dispersions: A review of amorphization, crystallization, stabilization, solid-state characterization, and aqueous solubilization of biopharmaceutical classification system class II drugs. J Pharm Sci 2016; 105(9): 2527-44.
[http://dx.doi.org/10.1016/j.xphs.2015.10.008] [PMID: 26886314]
[26]
Tanaka H, Ueda H. Co-Amorphous solid dispersion system for improvement in dissolution profile of N-(((1r,4r)-4-((6-fluorobenzo[d]oxazol-2-yl)amino)cyclohexyl)methyl)-2-methyl- propane-2-sulfonamide as a neuropeptide Y5 receptor antagonist. Pharmaceutics 2024; 16(10): 1293.
[http://dx.doi.org/10.3390/pharmaceutics16101293] [PMID: 39458622]
[27]
Alonzo DE, Gao Y, Zhou D, Mo H, Zhang GGZ, Taylor LS. Dissolution and precipitation behavior of amorphous solid dispersions. J Pharm Sci 2011; 100(8): 3316-31.
[http://dx.doi.org/10.1002/jps.22579] [PMID: 21607951]
[28]
Jadhav S, Bahl D, Stevens LL. Coformer-dependent physical stability in a series of naringenin-based coamorphous materials with caffeine, theophylline, and theobromine. Pharm Res 2023; 40(12): 2847-58.
[http://dx.doi.org/10.1007/s11095-023-03562-5] [PMID: 37505378]
[29]
Yu D, Nie H, Hoag SW. Comprehensive evaluation of polymer types and ratios in spray-dried dispersions: Compaction, dissolution, and physical stability. Int J Pharm 2024; 650123674.
[http://dx.doi.org/10.1016/j.ijpharm.2023.123674] [PMID: 38061497]
[30]
Tian B, Tang X, Taylor LS. Investigating the correlation between miscibility and physical stability of amorphous solid dispersions using fluorescence-based techniques. Mol Pharm 2016; 13(11): 3988-4000.
[http://dx.doi.org/10.1021/acs.molpharmaceut.6b00803] [PMID: 27700109]
[31]
Rumondor ACF, Taylor LS. Effect of polymer hygroscopicity on the phase behavior of amorphous solid dispersions in the presence of moisture. Mol Pharm 2010; 7(2): 477-90.
[http://dx.doi.org/10.1021/mp9002283] [PMID: 20039693]
[32]
Shi Q, Wang Y, Moinuddin SM, Feng X, Ahsan F. Co-amorphous drug delivery systems: A review of physical stability, in vitro and in vivo performance. AAPS PharmSciTech 2022; 23(7): 259.
[http://dx.doi.org/10.1208/s12249-022-02421-7] [PMID: 36123515]
[33]
Cao J, Zhang S, Hao Y, et al. Amorphous solid dispersion preparation via coprecipitation improves the dissolution, oral bioavailability, and intestinal health enhancement properties of magnolol. Poult Sci 2023; 102(6): 102676.
[http://dx.doi.org/10.1016/j.psj.2023.102676] [PMID: 37104903]
[34]
Nielsen RB, Larsen BS, Holm R, et al. Increased bioavailability of a P-gp substrate: Co-release of etoposide and zosuquidar from amorphous solid dispersions. Int J Pharm 2023; 642123094.
[http://dx.doi.org/10.1016/j.ijpharm.2023.123094] [PMID: 37263451]
[35]
Li J, Wang Y, Yu D. Effects of additives on the physical stability and dissolution of polymeric amorphous solid dispersions: A review. AAPS PharmSciTech 2023; 24(7): 175.
[http://dx.doi.org/10.1208/s12249-023-02622-8] [PMID: 37603110]
[36]
Guo W, Dong X, Li Y, et al. Co-amorphous formulation of dipyridamole with p-hydroxybenzoic acid: Underlying molecular mechanisms, physical stability, dissolution behavior and pharmacokinetic study. Eur J Pharm Biopharm 2023; 184: 139-49.
[http://dx.doi.org/10.1016/j.ejpb.2023.01.018] [PMID: 36709922]
[37]
Pisay M, Padya S, Mutalik S, Koteshwara KB. Stability challenges of amorphous solid dispersions of drugs: A critical review on mechanistic aspects. Crit Rev Ther Drug Carrier Syst 2024; 41(3): 45-94.
[http://dx.doi.org/10.1615/CritRevTherDrugCarrierSyst.2023039877] [PMID: 38037820]
[38]
Fung M, Be̅rziņš K, Suryanarayanan R. Physical stability and dissolution behavior of ketoconazole–organic acid coamorphous systems. Mol Pharm 2018; 15(5): 1862-9.
[http://dx.doi.org/10.1021/acs.molpharmaceut.8b00035] [PMID: 29528656]
[39]
Han J, Tang M, Yang Y, et al. Amorphous solid dispersions: Stability mechanism, design strategy and key production technique of hot melt extrusion. Int J Pharm 2023; 646123490.
[http://dx.doi.org/10.1016/j.ijpharm.2023.123490] [PMID: 37805146]
[40]
Tomar D, Kumar S. Designing novel piperine-vanillin nano-crystals for bioavailability enhancement. Inorg Nano-Met Chem 2025; 55(3): 319-28.
[http://dx.doi.org/10.1080/24701556.2023.2267541]
[41]
Karagianni A, Kachrimanis K, Nikolakakis I. Co-amorphous solid dispersions for solubility and absorption improvement of drugs: composition, preparation, characterization and formulations for oral delivery. Pharmaceutics 2018; 10(3): 98.
[http://dx.doi.org/10.3390/pharmaceutics10030098] [PMID: 30029516]
[42]
Jensen K, Löbmann K, Rades T, Grohganz H. Improving co-amorphous drug formulations by the addition of the highly water soluble amino Acid, proline. Pharmaceutics 2014; 6(3): 416-35.
[http://dx.doi.org/10.3390/pharmaceutics6030416] [PMID: 25025400]
[43]
Pardhi E, Tomar DS, Khemchandani R, Samanthula G, Singh PK, Mehra NK. Design, development and characterization of the Apremilast and Indomethacin coamorphous system. J Mol Struct 2024; 1299137045.
[http://dx.doi.org/10.1016/j.molstruc.2023.137045]
[44]
Dengale SJ, Ranjan OP, Hussen SS, et al. Preparation and characterization of co-amorphous ritonavir–indomethacin systems by solvent evaporation technique: Improved dissolution behavior and physical stability without evidence of intermolecular interactions. Eur J Pharm Sci 2014; 62: 57-64.
[http://dx.doi.org/10.1016/j.ejps.2014.05.015] [PMID: 24878386]
[45]
Chaudhari KR, Savjani JK, Savjani KT, Dahiya S, Bhangale JO. Enhanced solubility and dissolution of drug-drug cocrystals of lopinavir-ritonavir. IJPER 2023; 57(2s): s292-300.
[http://dx.doi.org/10.5530/ijper.57.2s.33]
[46]
Shelke R, Velagacherla V, Nayak UY. Recent advances in dual-drug co-amorphous systems. Drug Discov Today 2024; 29(2): 103863.
[http://dx.doi.org/10.1016/j.drudis.2023.103863] [PMID: 38141778]
[47]
Ngilirabanga JB, Samsodien H. Pharmaceutical co‐crystal: An alternative strategy for enhanced physicochemical properties and drug synergy. Nano Select 2021; 2(3): 512-26.
[http://dx.doi.org/10.1002/nano.202000201]
[48]
Dar AA, Lone SH, Ahmad I, Ahangar AA, Ganie AA, Femina C. Engineering the solid-state luminescence of organic crystals and cocrystals. Mater Adv 2024; 5(3): 1056-64.
[http://dx.doi.org/10.1039/D3MA00853C]
[49]
Dhondale MR, Thakor P, Nambiar AG, et al. Co-crystallization approach to enhance the stability of moisture-sensitive drugs. Pharmaceutics 2023; 15(1): 189.
[http://dx.doi.org/10.3390/pharmaceutics15010189] [PMID: 36678819]
[50]
Queiroz LHS, Barros RS, de Sousa FF, Lage MR, Sarraguça MC, Ribeiro PRS. Preparation and characterization of a rifampicin coamorphous material with tromethamine coformer: An experimental–theoretical study. Mol Pharm 2024; 21(3): 1272-84.
[http://dx.doi.org/10.1021/acs.molpharmaceut.3c00947] [PMID: 38361428]
[51]
Pajula K, Hyyryläinen J, Koistinen A, Leskinen JTT, Korhonen O. Detection of amorphous-amorphous phase separation in small molecular co-amorphous mixtures with SEM-EDS. Eur J Pharm Biopharm 2020; 150: 43-9.
[http://dx.doi.org/10.1016/j.ejpb.2020.03.002] [PMID: 32151730]
[52]
Gniado K, MacFhionnghaile P, McArdle P, Erxleben A. The natural bile acid surfactant sodium taurocholate (NaTC) as a coformer in coamorphous systems: Enhanced physical stability and dissolution behavior of coamorphous drug-NaTc systems. Int J Pharm 2018; 535(1-2): 132-9.
[http://dx.doi.org/10.1016/j.ijpharm.2017.10.049] [PMID: 29107615]
[53]
Van Duong T, Ni Z, Taylor LS. Phase behavior and crystallization kinetics of a poorly water-soluble weakly basic drug as a function of supersaturation and media composition. Mol Pharm 2022; 19(4): 1146-59.
[http://dx.doi.org/10.1021/acs.molpharmaceut.1c00927] [PMID: 35319221]
[54]
Jensen KT, Larsen FH, Löbmann K, Rades T, Grohganz H. Influence of variation in molar ratio on co-amorphous drug-amino acid systems. Eur J Pharm Biopharm 2016; 107: 32-9.
[http://dx.doi.org/10.1016/j.ejpb.2016.06.020] [PMID: 27368747]
[55]
Dengale SJ, Hussen SS, Krishna BSM, Musmade PB, Gautham Shenoy G, Bhat K. Fabrication, solid state characterization and bioavailability assessment of stable binary amorphous phases of Ritonavir with Quercetin. Eur J Pharm Biopharm 2015; 89: 329-38.
[http://dx.doi.org/10.1016/j.ejpb.2014.12.025] [PMID: 25542681]
[56]
Han Y, Pan Y, Lv J, Guo W, Wang J. Powder grinding preparation of co-amorphous β-azelnidipine and maleic acid combination: Molecular interactions and physicochemical properties. Powder Technol 2016; 291: 110-20.
[http://dx.doi.org/10.1016/j.powtec.2015.11.068]
[57]
Furuishi T, Sato-Hata N, Fukuzawa K, Yonemochi E. Characterization of co-amorphous carvedilol–maleic acid system prepared by solvent evaporation. Pharm Dev Technol 2023; 28(3-4): 309-17.
[http://dx.doi.org/10.1080/10837450.2023.2194406] [PMID: 36946594]
[58]
Beyer A, Grohganz H, Löbmann K, Rades T, Leopold CS. Improvement of the physicochemical properties of co-amorphous naproxen-indomethacin by naproxen-sodium. Int J Pharm 2017; 526(1-2): 88-94.
[http://dx.doi.org/10.1016/j.ijpharm.2017.04.011] [PMID: 28392278]
[59]
Zemánková A, Hassouna F, Klajmon M, Fulem M. Solid–liquid equilibrium in co-amorphous systems: Experiment and prediction. Molecules 2023; 28(6): 2492.
[http://dx.doi.org/10.3390/molecules28062492] [PMID: 36985463]
[60]
Chen H, Pui Y, Liu C, et al. Moisture-induced amorphous phase separation of amorphous solid dispersions: Molecular mechanism, microstructure, and its impact on dissolution performance. J Pharm Sci 2018; 107(1): 317-26.
[http://dx.doi.org/10.1016/j.xphs.2017.10.028] [PMID: 29107047]
[61]
Patel NG, Serajuddin ATM. Moisture sorption by polymeric excipients commonly used in amorphous solid dispersion and its effect on glass transition temperature: I. Polyvinylpyrrolidone and related copolymers. Int J Pharm 2022; 616121532.
[http://dx.doi.org/10.1016/j.ijpharm.2022.121532] [PMID: 35121046]
[62]
Nair AR, Lakshman YD, Anand VSK, Sree KSN, Bhat K, Dengale SJ. Overview of extensively employed polymeric carriers in solid dispersion technology. AAPS PharmSciTech 2020; 21(8): 309.
[http://dx.doi.org/10.1208/s12249-020-01849-z] [PMID: 33161493]
[63]
Petry I, Löbmann K, Grohganz H, Rades T, Leopold CS. Undesired co-amorphisation of indomethacin and arginine during combined storage at high humidity conditions. Int J Pharm 2018; 544(1): 172-80.
[http://dx.doi.org/10.1016/j.ijpharm.2018.04.026] [PMID: 29669257]
[64]
Fael H, Demirel AL. Tannic acid as a co-former in co-amorphous systems: Enhancing their physical stability, solubility and dissolution behavior. Int J Pharm 2020; 581119284.
[http://dx.doi.org/10.1016/j.ijpharm.2020.119284] [PMID: 32243965]
[65]
da Costa NF, Daniels R, Fernandes AI, Pinto JF. Amorphous and co-amorphous olanzapine stability in formulations intended for wet granulation and pelletization. Int J Mol Sci 2022; 23(18): 10234.
[http://dx.doi.org/10.3390/ijms231810234] [PMID: 36142179]
[66]
Goodwin MJ, Musa OM, Berry DJ, Steed JW. Small-molecule povidone analogues in coamorphous pharmaceutical phases. Cryst Growth Des 2018; 18(2): 701-9.
[http://dx.doi.org/10.1021/acs.cgd.7b01062]
[67]
Shi Q, Chen H, Wang Y, Wang R, Xu J, Zhang C. Amorphous solid dispersions: Role of the polymer and its importance in physical stability and in vitro performance. Pharmaceutics 2022; 14(8): 1747.
[http://dx.doi.org/10.3390/pharmaceutics14081747] [PMID: 36015373]
[68]
Rawat N, Singh SK, Baldi A. Development and characterization of enteric polymer-based solid dispersion for cholecalciferol delivery. Lett Drug Des Discov 2024; 21(5): 918-27.
[http://dx.doi.org/10.2174/1570180820666230130093355]
[69]
Gupta A, Paudwal G, Dolkar R, Lewis S, Gupta PN. Recent advances in the surfactant and controlled release polymer-based solid dispersion. Curr Pharm Des 2022; 28(20): 1643-59.
[http://dx.doi.org/10.2174/1381612828666220223095417] [PMID: 35209818]
[70]
Xu X, Rades T, Grohganz H. Thermal investigation on hydrated co-amorphous systems of nicotinamide and prilocaine. Eur J Pharm Biopharm 2023; 186: 1-6.
[http://dx.doi.org/10.1016/j.ejpb.2023.02.015] [PMID: 36878408]
[71]
Kapoor DU, Singh S, Sharma P, Prajapati BG. Amorphization of low soluble drug with amino acids to improve its therapeutic efficacy: A state-of-art-review. AAPS PharmSciTech 2023; 24(8): 253.
[http://dx.doi.org/10.1208/s12249-023-02709-2] [PMID: 38062314]
[72]
Hildebrand JH, Solubility XIV. Experimental tests of a general equation for solubility. J Am Chem Soc 1935; 57(5): 866-71.
[http://dx.doi.org/10.1021/ja01308a022]
[73]
Adamska K, Voelkel A. Inverse gas chromatographic determination of solubility parameters of excipients. Int J Pharm 2005; 304(1-2): 11-7.
[http://dx.doi.org/10.1016/j.ijpharm.2005.03.040] [PMID: 16183222]
[74]
Marsac PJ, Li T, Taylor LS. Estimation of drug-polymer miscibility and solubility in amorphous solid dispersions using experimentally determined interaction parameters. Pharm Res 2009; 26(1): 139-51.
[http://dx.doi.org/10.1007/s11095-008-9721-1] [PMID: 18779927]
[75]
Thakral S, Thakral NK. Prediction of drug-polymer miscibility through the use of solubility parameter based Flory-Huggins interaction parameter and the experimental validation: PEG as model polymer. J Pharm Sci 2013; 102(7): 2254-63.
[http://dx.doi.org/10.1002/jps.23583] [PMID: 23649486]
[76]
Sun Y, Tao J, Zhang GGZ, Yu L. Solubilities of crystalline drugs in polymers: An improved analytical method and comparison of solubilities of indomethacin and nifedipine in PVP, PVP/VA, and PVAc. J Pharm Sci 2010; 99(9): 4023-31.
[http://dx.doi.org/10.1002/jps.22251] [PMID: 20607809]
[77]
Saberi A, Kouhjani M, Yari D, et al. Development, recent advances, and updates in binary, ternary co-amorphous systems, and ternary solid dispersions. J Drug Deliv Sci Technol 2023; 86104746.
[http://dx.doi.org/10.1016/j.jddst.2023.104746]
[78]
Baird JA, Taylor LS. Evaluation of amorphous solid dispersion properties using thermal analysis techniques. Adv Drug Deliv Rev 2012; 64(5): 396-421.
[http://dx.doi.org/10.1016/j.addr.2011.07.009] [PMID: 21843564]
[79]
Wu W, Löbmann K, Rades T, Grohganz H. On the role of salt formation and structural similarity of co-formers in co-amorphous drug delivery systems. Int J Pharm 2018; 535(1-2): 86-94.
[http://dx.doi.org/10.1016/j.ijpharm.2017.10.057] [PMID: 29102703]
[80]
Vallaster B, Engelsing F, Grohganz H. Influence of water and trehalose on α- and β-relaxation of freeze-dried lysozyme formulations. Eur J Pharm Biopharm 2024; 194: 1-8.
[http://dx.doi.org/10.1016/j.ejpb.2023.11.019] [PMID: 38029940]
[81]
Dhaval M, Dudhat K, Soniwala M, Dudhrejiya A. shah S, Prajapati B. A review on stabilization mechanism of amorphous form based drug delivery system. Mater Today Commun 2023; 37107411.
[http://dx.doi.org/10.1016/j.mtcomm.2023.107411]
[82]
Riekes MK, Engelen A, Appeltans B, Rombaut P, Stulzer HK, Van den Mooter G. New perspectives for fixed dose combinations of poorly water-soluble compounds: A case study with ezetimibe and lovastatin. Pharm Res 2016; 33(5): 1259-75.
[http://dx.doi.org/10.1007/s11095-016-1870-z] [PMID: 26857899]
[83]
Partheniadis I, Nikolakakis I. Development and characterization of co-amorphous griseofulvin/L-leucin by modified solvent processing hot-melt extrusion. Int J Pharm 2024; 652123824.
[http://dx.doi.org/10.1016/j.ijpharm.2024.123824] [PMID: 38246478]
[84]
Pacułt J, Rams-Baron M, Chmiel K, et al. How can we improve the physical stability of co-amorphous system containing flutamide and bicalutamide? The case of ternary amorphous solid dispersions. Eur J Pharm Sci 2021; 159105697.
[http://dx.doi.org/10.1016/j.ejps.2020.105697] [PMID: 33568330]
[85]
Janssens S, Nagels S, Armas HN, D’Autry W, Van Schepdael A, Van den Mooter G. Formulation and characterization of ternary solid dispersions made up of Itraconazole and two excipients, TPGS 1000 and PVPVA 64, that were selected based on a supersaturation screening study. Eur J Pharm Biopharm 2008; 69(1): 158-66.
[http://dx.doi.org/10.1016/j.ejpb.2007.11.004] [PMID: 18164929]
[86]
Budiman A, Lailasari E, Nurani NV, et al. Ternary solid dispersions: A review of the preparation, characterization, mechanism of drug release, and physical stability. Pharmaceutics 2023; 15(8): 2116.
[http://dx.doi.org/10.3390/pharmaceutics15082116] [PMID: 37631330]
[87]
Su M, Xia Y, Shen Y, et al. A novel drug–drug coamorphous system without molecular interactions: improve the physicochemical properties of tadalafil and repaglinide. RSC Advances 2020; 10(1): 565-83.
[http://dx.doi.org/10.1039/C9RA07149K]
[88]
Renuka, Singh SK, Gulati M, Narang R. Stable amorphous binary systems of glipizide and atorvastatin powders with enhanced dissolution profiles: formulation and characterization. Pharm Dev Technol 2017; 22(1): 13-25.
[http://dx.doi.org/10.3109/10837450.2015.1125921] [PMID: 26708555]
[89]
Liu J, Hwu E, Bannow J, Grohganz H, Rades T. Impact of molecular surface diffusion on the physical stability of co-amorphous systems. Mol Pharm 2022; 19(4): 1183-90.
[http://dx.doi.org/10.1021/acs.molpharmaceut.1c00973] [PMID: 35230110]
[90]
Hu Y, Jiang C, Li B, et al. A novel lurasidone hydrochloride–shikimic acid co-amorphous system formed by hydrogen-bonding interaction with the retained pH-dependent solubility behavior. CrystEngComm 2020; 22(35): 5841-53.
[http://dx.doi.org/10.1039/D0CE00952K]
[91]
Turek M, Różycka-Sokołowska E, Koprowski M, Marciniak B, Bałczewski P. Role of hydrogen bonds in formation of co-amorphous valsartan/nicotinamide compositions of high solubility and durability with anti-hypertension and anti-COVID-19 potential. Mol Pharm 2021; 18(5): 1970-84.
[http://dx.doi.org/10.1021/acs.molpharmaceut.0c01096] [PMID: 33792313]
[92]
Deng Y, Deng W, Huang W, et al. Norfloxacin co-amorphous salt systems: Effects of molecular descriptors on the formation and physical stability of co-amorphous systems. Chem Eng Sci 2022; 253117549.
[http://dx.doi.org/10.1016/j.ces.2022.117549]
[93]
Hu D, Chen X, Li D, Zhang H, Duan Y, Huang Y. Tranilast-matrine co-amorphous system: Strong intermolecular interactions, improved solubility, and physiochemical stability. Int J Pharm 2023; 635122707.
[http://dx.doi.org/10.1016/j.ijpharm.2023.122707] [PMID: 36764418]
[94]
Suleiman Alsalhi M, Royall PG, Al-Obaidi H, Alsalhi A, Cilibrizzi A, Chan KLA. Non-salt based co-amorphous formulation produced by freeze-drying. Int J Pharm 2023; 645123404.
[http://dx.doi.org/10.1016/j.ijpharm.2023.123404] [PMID: 37714312]
[95]
Feng Y, Li B, Yang L, Liu Y. Co-amorphous delivery systems based on curcumin and hydroxycinnamic acids: Stabilization, solubilization, and controlled release. Lebensm Wiss Technol 2022; 170114091.
[http://dx.doi.org/10.1016/j.lwt.2022.114091]
[96]
Deng Y, Liu S, Jiang Y, Martins ICB, Rades T. Recent advances in co-former screening and formation prediction of multicomponent solid forms of low molecular weight drugs. Pharmaceutics 2023; 15(9): 2174.
[http://dx.doi.org/10.3390/pharmaceutics15092174] [PMID: 37765145]
[97]
Chambers LI, Grohganz H, Palmelund H, et al. Predictive identification of co-formers in co-amorphous systems. Eur J Pharm Sci 2021; 157105636.
[http://dx.doi.org/10.1016/j.ejps.2020.105636] [PMID: 33160046]
[98]
Han J, Wei Y, Lu Y, et al. Co-amorphous systems for the delivery of poorly water-soluble drugs: Recent advances and an update. Expert Opin Drug Deliv 2020; 17(10): 1411-35.
[http://dx.doi.org/10.1080/17425247.2020.1796631] [PMID: 32683996]
[99]
Shi X, Zhou X, Shen S, et al. Improved in vitro and in vivo properties of telmisartan in the co-amorphous system with hydrochlorothiazide: A potential drug-drug interaction mechanism prediction. Eur J Pharm Sci 2021; 161105773.
[http://dx.doi.org/10.1016/j.ejps.2021.105773] [PMID: 33640500]
[100]
Li B, Wang Y, Feng Y, et al. Design and molecular insights of drug-active metabolite based co-amorphous formulation: A case study of toltrazuril-ponazuril co-amorphous. Int J Pharm 2022; 615121475.
[http://dx.doi.org/10.1016/j.ijpharm.2022.121475] [PMID: 35041914]
[101]
Laitinen R, Löbmann K, Grohganz H, Priemel P, Strachan CJ, Rades T. Supersaturating drug delivery systems: The potential of co-amorphous drug formulations. Int J Pharm 2017; 532(1): 1-12.
[http://dx.doi.org/10.1016/j.ijpharm.2017.08.123] [PMID: 28870764]
[102]
Löbmann K, Grohganz H, Laitinen R, Strachan C, Rades T. Amino acids as co-amorphous stabilizers for poorly water soluble drugs – Part 1: Preparation, stability and dissolution enhancement. Eur J Pharm Biopharm 2013; 85(3): 873-81.
[http://dx.doi.org/10.1016/j.ejpb.2013.03.014] [PMID: 23537574]
[103]
Allesø M, Chieng N, Rehder S, Rantanen J, Rades T, Aaltonen J. Enhanced dissolution rate and synchronized release of drugs in binary systems through formulation: Amorphous naproxen–cimetidine mixtures prepared by mechanical activation. J Control Release 2009; 136(1): 45-53.
[http://dx.doi.org/10.1016/j.jconrel.2009.01.027] [PMID: 19331842]
[104]
Löbmann K, Laitinen R, Grohganz H, Gordon KC, Strachan C, Rades T. Coamorphous drug systems: Enhanced physical stability and dissolution rate of indomethacin and naproxen. Mol Pharm 2011; 8(5): 1919-28.
[http://dx.doi.org/10.1021/mp2002973] [PMID: 21815614]
[105]
Jensen KT, Blaabjerg LI, Lenz E, et al. Preparation and characterization of spray-dried co-amorphous drug–amino acid salts. J Pharm Pharmacol 2016; 68(5): 615-24.
[http://dx.doi.org/10.1111/jphp.12458] [PMID: 26245703]
[106]
Paluch KJ, McCabe T, Müller-Bunz H, Corrigan OI, Healy AM, Tajber L. Formation and physicochemical properties of crystalline and amorphous salts with different stoichiometries formed between ciprofloxacin and succinic acid. Mol Pharm 2013; 10(10): 3640-54.
[http://dx.doi.org/10.1021/mp400127r] [PMID: 23947816]
[107]
Trasi NS, Taylor LS. Thermodynamics of highly supersaturated aqueous solutions of poorly water-soluble drugs—Impact of a second drug on the solution phase behavior and implications for combination products. J Pharm Sci 2015; 104(8): 2583-93.
[http://dx.doi.org/10.1002/jps.24528] [PMID: 26059413]
[108]
Trasi NS, Taylor LS. Dissolution performance of binary amorphous drug combinations—Impact of a second drug on the maximum achievable supersaturation. Int J Pharm 2015; 496(2): 282-90.
[http://dx.doi.org/10.1016/j.ijpharm.2015.10.026] [PMID: 26456250]
[109]
Alhalaweh A, Bergström CAS, Taylor LS. Compromised in vitro dissolution and membrane transport of multidrug amorphous formulations. J Control Release 2016; 229: 172-82.
[http://dx.doi.org/10.1016/j.jconrel.2016.03.028] [PMID: 27006280]
[110]
Arca HÇ, Mosquera-Giraldo LI, Dahal D, Taylor LS, Edgar KJ. Multidrug, anti-HIV amorphous solid dispersions: Nature and mechanisms of impacts of drugs on each other’s solution concentrations. Mol Pharm 2017; 14(11): 3617-27.
[http://dx.doi.org/10.1021/acs.molpharmaceut.7b00203] [PMID: 28872867]
[111]
Ojarinta R, Heikkinen AT, Sievänen E, Laitinen R. Dissolution behavior of co-amorphous amino acid-indomethacin mixtures: The ability of amino acids to stabilize the supersaturated state of indomethacin. Eur J Pharm Biopharm 2017; 112: 85-95.
[http://dx.doi.org/10.1016/j.ejpb.2016.11.023] [PMID: 27888143]
[112]
Moinuddin SM, Ruan S, Huang Y, et al. Facile formation of co-amorphous atenolol and hydrochlorothiazide mixtures via cryogenic-milling: Enhanced physical stability, dissolution and pharmacokinetic profile. Int J Pharm 2017; 532(1): 393-400.
[http://dx.doi.org/10.1016/j.ijpharm.2017.09.020] [PMID: 28893583]
[113]
Zhang Y, Gao Y, Du X, Guan R, He Z, Liu H. Combining Co-amorphous-based spray drying with inert carriers to achieve improved bioavailability and excellent downstream manufacturability. Pharmaceutics 2020; 12(11): 1063.
[http://dx.doi.org/10.3390/pharmaceutics12111063] [PMID: 33171591]
[114]
Lodagekar A, Chavan RB, Mannava MKC, et al. Co amorphous valsartan nifedipine system: Preparation, characterization, in vitro and in vivo evaluation. Eur J Pharm Sci 2019; 139105048.
[http://dx.doi.org/10.1016/j.ejps.2019.105048] [PMID: 31446077]
[115]
Zhang X, Wu J, Wei J, et al. High-performance biobased vinyl ester resin and its fiberglass-reinforced composite with high glass transition temperature (Tg), excellent flame retardancy and mechanical properties. Polym Degrad Stabil 2023; 207110209.
[http://dx.doi.org/10.1016/j.polymdegradstab.2022.110209]
[116]
Rusdin A, Mohd Gazzali A, Ain Thomas N, et al. Advancing drug delivery paradigms: Polyvinyl Pyrolidone (PVP)-based amorphous solid dispersion for enhanced physicochemical properties and therapeutic efficacy. Polymers 2024; 16(2): 286.
[http://dx.doi.org/10.3390/polym16020286] [PMID: 38276694]
[117]
Kurakula M, Rao GSNK. Pharmaceutical assessment of polyvinylpyrrolidone (PVP): As excipient from conventional to controlled delivery systems with a spotlight on COVID-19 inhibition. J Drug Deliv Sci Technol 2020; 60102046.
[http://dx.doi.org/10.1016/j.jddst.2020.102046] [PMID: 32905026]
[118]
Franco P, Reverchon E, De Marco I. PVP/ketoprofen coprecipitation using supercritical antisolvent process. Powder Technol 2018; 340: 1-7.
[http://dx.doi.org/10.1016/j.powtec.2018.09.007]
[119]
Samsoen S, Dudognon É, Le Fer G, Fournier D, Woisel P, Affouard F. Impact of the polymer dispersity on the properties of curcumin/polyvinylpyrrolidone amorphous solid dispersions. Int J Pharm 2024; 653123895.
[http://dx.doi.org/10.1016/j.ijpharm.2024.123895] [PMID: 38346598]
[120]
Pyo YC, Nguyen TN, Lee YS, Choi YE, Park JS. Design of esomeprazole solid dispersion for improved dissolution and bioavailability using the supercritical anti-solvent technique. J Drug Deliv Sci Technol 2023; 88104889.
[http://dx.doi.org/10.1016/j.jddst.2023.104889]
[121]
Singh P. Preparation, characterization and dissolution study of spray dried solid dispersions of simvastatin with PVP K25 and AEROSIL 200. J Med Pharm Allied Sci 2021; 10(6): 3806-12.
[http://dx.doi.org/10.22270/jmpas.V10I6.1374]
[122]
Shi X, Xu T, Huang W, Fan B, Sheng X. Stability and bioavailability enhancement of telmisartan ternary solid dispersions: The synergistic effect of polymers and drug-polymer(s) interactions. AAPS PharmSciTech 2019; 20(4): 143.
[http://dx.doi.org/10.1208/s12249-019-1358-3] [PMID: 30887265]
[123]
Guo Y, Patel H, Saraswat A, Mateti KV, Patel K, Squillante E. Screening and optimization of supercritical fluid process for the preparation of albendazole solid dispersion. J Drug Deliv Sci Technol 2023; 88104852.
[http://dx.doi.org/10.1016/j.jddst.2023.104852]
[124]
AL-Japairai K, Hamed Almurisi S, Mahmood S, et al. Strategies to improve the stability of amorphous solid dispersions in view of the hot melt extrusion (HME) method. Int J Pharm 2023; 647123536.
[http://dx.doi.org/10.1016/j.ijpharm.2023.123536] [PMID: 37865133]
[125]
Aldeeb RAE, Mahdy MAEG, El-Nahas HM, Musallam AA. Design of mirtazapine solid dispersion with different carriers’ systems: Optimization, in vitro evaluation, and bioavailability assessment. Drug Deliv Transl Res 2023; 13(9): 2340-52.
[http://dx.doi.org/10.1007/s13346-023-01316-9] [PMID: 36940079]
[126]
Bejaoui M, Kalfat R, Galai H. The effect of adding PVP to the binary solid dispersion (Indomethacin: Kaolin) on the formation of physically stable amorphous drug. J Pharm Innov 2022; 17(3): 736-46.
[http://dx.doi.org/10.1007/s12247-021-09553-6]
[127]
Lu W, Rades T, Rantanen J, Yang M. Inhalable co-amorphous budesonide-arginine dry powders prepared by spray drying. Int J Pharm 2019; 565: 1-8.
[http://dx.doi.org/10.1016/j.ijpharm.2019.04.036] [PMID: 30999050]
[128]
Zi P, Zhang C, Ju C, et al. Solubility and bioavailability enhancement study of lopinavir solid dispersion matrixed with a polymeric surfactant - Soluplus. Eur J Pharm Sci 2019; 134: 233-45.
[http://dx.doi.org/10.1016/j.ejps.2019.04.022] [PMID: 31028820]
[129]
Espinar FJO, Lavilla CB, Fernández GB, Tomé VD, Otero XG. Formulation strategies to improve the bioavailability of poorly absorbed drugs. Dosage Forms, Formulation Developments and Regulations. Elsevier 2024; pp. 223-55.
[http://dx.doi.org/10.1016/B978-0-323-91817-6.00008-5]
[130]
Budiman A, Rusdin A, Aulifa DL. Current techniques of water solubility improvement for antioxidant compounds and their correlation with its activity: Molecular pharmaceutics. Antioxidants 2023; 12(2): 378.
[http://dx.doi.org/10.3390/antiox12020378] [PMID: 36829937]
[131]
Pardhi VP, Pathak A, Jain K. Solid dispersions of bedaquiline fumarate to improve its pharmaceutical attributes: A comparative study between PEG and PVP. J Drug Deliv Sci Technol 2024; 94105461.
[http://dx.doi.org/10.1016/j.jddst.2024.105461]
[132]
Chen Q, Ji Y. Thermodynamic mechanism of physical stability of amorphous pharmaceutical formulations. Ind Eng Chem Res 2023; 62(3): 1596-605.
[http://dx.doi.org/10.1021/acs.iecr.2c02953]
[133]
Kalantri SS, Yadav MD. Advances in carbamazepine cocrystals: A review. Cryst Res Technol 2024; 59(4): 2300296.
[http://dx.doi.org/10.1002/crat.202300296]
[134]
Aung WT, Kopongpanich P, Boonkanokwong V. Supersaturable solid self-microemulsifying delivery systems of Astaxanthin via spray drying: Effects of polymers and solid carriers. AAPS PharmSciTech 2023; 24(8): 218.
[http://dx.doi.org/10.1208/s12249-023-02671-z] [PMID: 37891405]
[135]
Narala S, Nyavanandi D, Mandati P, et al. Preparation and in vitro evaluation of hot-melt extruded pectin-based pellets containing ketoprofen for colon targeting. Int J Pharm X 2023; 5100156.
[http://dx.doi.org/10.1016/j.ijpx.2022.100156] [PMID: 36636366]
[136]
Lee SK, Ha ES, Park H, et al. Preparation of hot-melt-extruded solid dispersion based on pre-formulation strategies and its enhanced therapeutic efficacy. Pharmaceutics 2023; 15(12): 2704.
[http://dx.doi.org/10.3390/pharmaceutics15122704] [PMID: 38140045]
[137]
Tsiaxerli A, Karagianni A, Ouranidis A, Kachrimanis K. Polyelectrolyte matrices in the modulation of intermolecular electrostatic interactions for amorphous solid dispersions: A comprehensive review. Pharmaceutics 2021; 13(9): 1467.
[http://dx.doi.org/10.3390/pharmaceutics13091467] [PMID: 34575543]
[138]
Chen Z, Nie H, Benmore CJ, et al. Probing molecular packing of amorphous pharmaceutical solids using X-ray atomic pair distribution function and solid-state NMR. Mol Pharm 2023; 20(11): 5763-77.
[http://dx.doi.org/10.1021/acs.molpharmaceut.3c00628] [PMID: 37800667]
[139]
Saha SK, Joshi A, Singh R, Dubey K. Review of industrially recognized polymers and manufacturing processes for amorphous solid dispersion based formulations. Pharm Dev Technol 2023; 28(7): 678-96.
[http://dx.doi.org/10.1080/10837450.2023.2233595] [PMID: 37427544]
[140]
Jain SK, Jain AK, Rajpoot K. Expedition of Eudragit® polymers in the development of novel drug delivery systems. Curr Drug Deliv 2020; 17(6): 448-69.
[http://dx.doi.org/10.2174/1567201817666200512093639] [PMID: 32394836]
[141]
LaVan D, Yi F, Adams T, et al. Abstracts of the 2023 49th annual NATAS conference. Polymers 2023; 15(15): 3250.
[http://dx.doi.org/10.3390/polym15153250] [PMID: 37571144]
[142]
Abdelquader MM, Li S, Andrews GP, Jones DS. Therapeutic deep eutectic solvents: A comprehensive review of their thermodynamics, microstructure and drug delivery applications. Eur J Pharm Biopharm 2023; 186: 85-104.
[http://dx.doi.org/10.1016/j.ejpb.2023.03.002] [PMID: 36907368]
[143]
Zong S, Liu Y, Park HJ, Ye M, Li J. Curcumin solid dispersion based on three model acrylic polymers: formulation and release properties. Braz J Pharm Sci 2022; 58(1-2)
[http://dx.doi.org/10.1590/s2175-97902022e18946]
[144]
Rosiak N, Tykarska E, Cielecka-Piontek J. The study of amorphous Kaempferol dispersions involving FT-IR spectroscopy. Int J Mol Sci 2023; 24(24): 17155.
[http://dx.doi.org/10.3390/ijms242417155] [PMID: 38138984]
[145]
Tran P, Pyo YC, Kim DH, Lee SE, Kim JK, Park JS. Overview of the manufacturing methods of solid dispersion technology for improving the solubility of poorly water-soluble drugs and application to anticancer drugs. Pharmaceutics 2019; 11(3): 132.
[http://dx.doi.org/10.3390/pharmaceutics11030132] [PMID: 30893899]
[146]
Rédai EM, Sipos E, Vlad RA, Antonoaea P, Todoran N, Ciurba A. Development of co-amorphous loratadine–citric acid orodispersible drug formulations. Processes 2022; 10(12): 2722.
[http://dx.doi.org/10.3390/pr10122722]
[147]
Mali AJ, Patil S, Chellampillai B. Investigation of polyvinyl alcohol-polyethylene glycol graft copolymer as an advanced functional polymer in the development of perampanel orodispersible film. J Polym Res 2022; 29(4): 130.
[http://dx.doi.org/10.1007/s10965-022-02951-5]
[148]
Tan DK, Davis DA Jr, Miller DA, Williams RO III, Nokhodchi A. Innovations in thermal processing: Hot-melt extrusion and KinetiSol® dispersing. AAPS PharmSciTech 2020; 21(8): 312.
[http://dx.doi.org/10.1208/s12249-020-01854-2] [PMID: 33161479]
[149]
Thompson SA, Davis DA, DiNunzio JC, Martin C, Williams RO, Zhang F. Melt Extrusion. Formulating Poorly Water Soluble Drugs. Springer 2022; pp. 327-76.
[http://dx.doi.org/10.1007/978-3-030-88719-3_9]
[150]
Pardhi VP, Jain K. Impact of binary/ternary solid dispersion utilizing poloxamer 188 and TPGS to improve pharmaceutical attributes of bedaquiline fumarate. J Drug Deliv Sci Technol 2021; 62102349.
[http://dx.doi.org/10.1016/j.jddst.2021.102349]
[151]
Priyadarsini M, Avula PR. Amorphous solid dispersions of ritonavir by melt-quenching. Int J Health Sci 2022; 6(S8): 4020-34.
[http://dx.doi.org/10.53730/ijhs.v6nS8.13041]
[152]
Suknuntha K, Khumpirapang N, Tantishaiyakul V, Okonogi S. Solubility and physical stability enhancement of loratadine by preparation of co-amorphous solid dispersion with chlorpheniramine and polyvinylpyrrolidone. Pharmaceutics 2023; 15(11): 2558.
[http://dx.doi.org/10.3390/pharmaceutics15112558] [PMID: 38004537]
[153]
Holzapfel K, Rades T, Leopold CS. Co-amorphous systems consisting of indomethacin and the chiral co-former tryptophan: Solid-state properties and molecular mobilities. Int J Pharm 2023; 636122840.
[http://dx.doi.org/10.1016/j.ijpharm.2023.122840] [PMID: 36921746]
[154]
Heng W, Song Y, Luo M, et al. Mechanistic insights into the crystallization of coamorphous drug systems. J Control Release 2023; 354: 489-502.
[http://dx.doi.org/10.1016/j.jconrel.2023.01.019] [PMID: 36646287]
[155]
Lalge R, Kumar NSK, Suryanarayanan R. Implications of drug–polymer interactions on time–temperature–transformation: A tool to assess the crystallization propensity in amorphous solid dispersions. Mol Pharm 2023; 20(3): 1806-17.
[http://dx.doi.org/10.1021/acs.molpharmaceut.2c01004] [PMID: 36744878]
[156]
Deng Y, Luo W, Zheng Z, et al. Prediction of co-amorphous formation using non-bonded interaction energy: Molecular dynamic simulation and experimental validation. Chem Eng Sci 2023; 272118618.
[http://dx.doi.org/10.1016/j.ces.2023.118618]
[157]
Li J, Wang X, Yu D, Zhoujin Y, Wang K. Molecular complexes of drug combinations: A review of cocrystals, salts, coamorphous systems and amorphous solid dispersions. Int J Pharm 2023; 648123555.
[http://dx.doi.org/10.1016/j.ijpharm.2023.123555] [PMID: 37890646]
[158]
Di R, Rades T, Grohganz H. Destabilization of indomethacin-paracetamol co-amorphous systems by mechanical stress. Pharmaceutics 2023; 16(1): 67.
[http://dx.doi.org/10.3390/pharmaceutics16010067] [PMID: 38258078]
[159]
Sørensen CM, Rantanen J, Grohganz H. Compaction behavior of co-amorphous systems. Pharmaceutics 2023; 15(3): 858.
[http://dx.doi.org/10.3390/pharmaceutics15030858] [PMID: 36986718]
[160]
Bejaoui M, Djemi R, Kouass S, Galai H. Co-amorphous system (Paracetamol:Indomethacin): Investigations on physical stability and intermolecular interactions. Pharm Chem J 2023; 57(8): 1330-7.
[http://dx.doi.org/10.1007/s11094-024-03042-z]
[161]
Ruponen M, Visti M, Ojarinta R, Laitinen R. Permeability of glibenclamide through a PAMPA membrane: The effect of co-amorphization. Eur J Pharm Biopharm 2018; 129: 247-56.
[http://dx.doi.org/10.1016/j.ejpb.2018.06.007] [PMID: 29894814]
[162]
Iemtsev A, Zemánková A, Hassouna F, et al. Ball milling and hot-melt extrusion of indomethacin–l-arginine–vinylpyrrolidone-vinyl acetate copolymer: Solid-state properties and dissolution performance. Int J Pharm 2022; 613121424.
[http://dx.doi.org/10.1016/j.ijpharm.2021.121424] [PMID: 34968683]
[163]
Ojarinta R, Lerminiaux L, Laitinen R. Spray drying of poorly soluble drugs from aqueous arginine solution. Int J Pharm 2017; 532(1): 289-98.
[http://dx.doi.org/10.1016/j.ijpharm.2017.09.015] [PMID: 28890173]
[164]
Wu W, Löbmann K, Schnitzkewitz J, et al. Dipeptides as co-formers in co-amorphous systems. Eur J Pharm Biopharm 2019; 134: 68-76.
[http://dx.doi.org/10.1016/j.ejpb.2018.11.016] [PMID: 30468836]
[165]
Kasten G, Lobo L, Dengale S, Grohganz H, Rades T, Löbmann K. In vitro and in vivo comparison between crystalline and co-amorphous salts of naproxen-arginine. Eur J Pharm Biopharm 2018; 132: 192-9.
[http://dx.doi.org/10.1016/j.ejpb.2018.09.024] [PMID: 30266670]
[166]
Zhu S, Gao H, Babu S, Garad S. Co-amorphous formation of high-dose zwitterionic compounds with amino acids to improve solubility and enable parenteral delivery. Mol Pharm 2018; 15(1): 97-107.
[http://dx.doi.org/10.1021/acs.molpharmaceut.7b00738] [PMID: 29164901]
[167]
Huang Y, Zhang Q, Wang JR, Lin KL, Mei X. Amino acids as co-amorphous excipients for tackling the poor aqueous solubility of valsartan. Pharm Dev Technol 2017; 22(1): 69-76.
[http://dx.doi.org/10.3109/10837450.2016.1163390] [PMID: 27050301]
[168]
Pan Y, Pang W, Lv J, Wang J, Yang C, Guo W. Solid state characterization of azelnidipine–oxalic acid co-crystal and co-amorphous complexes: The effect of different azelnidipine polymorphs. J Pharm Biomed Anal 2017; 138: 302-15.
[http://dx.doi.org/10.1016/j.jpba.2017.02.005] [PMID: 28237872]
[169]
Ali AMA, Ali AA, Maghrabi IA. Clozapine-carboxylic acid plasticized co-amorphous dispersions: Preparation, characterization and solution stability evaluation. Acta Pharm 2015; 65(2): 133-46.
[http://dx.doi.org/10.1515/acph-2015-0014] [PMID: 26011930]
[170]
Ainurofiq A, Mauludin R, Mudhakir D, Soewandhi SN. A novel desloratadine-benzoic acid co-amorphous solid: Preparation, characterization, and stability evaluation. Pharmaceutics 2018; 10(3): 85.
[http://dx.doi.org/10.3390/pharmaceutics10030085] [PMID: 29986403]
[171]
Yamamoto K, Kojima T, Karashima M, Ikeda Y. Physicochemical evaluation and developability assessment of co-amorphouses of low soluble drugs and comparison to the co-crystals. Chem Pharm Bull (Tokyo) 2016; 64(12): 1739-46.
[http://dx.doi.org/10.1248/cpb.c16-00604] [PMID: 27733735]
[172]
Wang J, Chang R, Zhao Y, et al. Coamorphous loratadine-citric acid system with enhanced physical stability and bioavailability. AAPS PharmSciTech 2017; 18(7): 2541-50.
[http://dx.doi.org/10.1208/s12249-017-0734-0] [PMID: 28224393]
[173]
Maher EM, Ali AMA, Salem HF, Abdelrahman AA. In vitro/in vivo evaluation of an optimized fast dissolving oral film containing olanzapine co-amorphous dispersion with selected carboxylic acids. Drug Deliv 2016; 23(8): 3088-100.
[http://dx.doi.org/10.3109/10717544.2016.1153746] [PMID: 26960680]
[174]
Kulthe V, Chaudhari P, Aboul-Enein H. Freeze-dried amorphous dispersions for solubility enhancement of thermosensitive API having low molecular lipophilicity. Drug Res (Stuttg) 2014; 64(9): 493-8.
[http://dx.doi.org/10.1055/s-0033-1363249] [PMID: 24443307]
[175]
Al-Hamidi H, Edwards AA, Mohammad MA, Nokhodchi A. To enhance dissolution rate of poorly water-soluble drugs: Glucosamine hydrochloride as a potential carrier in solid dispersion formulations. Colloids Surf B Biointerfaces 2010; 76(1): 170-8.
[http://dx.doi.org/10.1016/j.colsurfb.2009.10.030] [PMID: 19945828]
[176]
Madgulkar A, Bandivadekar M, Shid T, Rao S. Sugars as solid dispersion carrier to improve solubility and dissolution of the BCS class II drug: clotrimazole. Drug Dev Ind Pharm 2016; 42(1): 28-38.
[http://dx.doi.org/10.3109/03639045.2015.1024683] [PMID: 25874729]
[177]
Kaminska E, Adrjanowicz K, Tarnacka M, et al. Impact of inter- and intramolecular interactions on the physical stability of indomethacin dispersed in acetylated saccharides. Mol Pharm 2014; 11(8): 2935-47.
[http://dx.doi.org/10.1021/mp500286b] [PMID: 25011022]
[178]
Kaminska E, Madejczyk O, Tarnacka M, Jurkiewicz K, Kaminski K, Paluch M. Studying of crystal growth and overall crystallization of naproxen from binary mixtures. Eur J Pharm Biopharm 2017; 113: 75-87.
[http://dx.doi.org/10.1016/j.ejpb.2016.12.014] [PMID: 28034808]
[179]
Zajc N, Obreza A, Bele M, Srčič S. Physical properties and dissolution behaviour of nifedipine/mannitol solid dispersions prepared by hot melt method. Int J Pharm 2005; 291(1-2): 51-8.
[http://dx.doi.org/10.1016/j.ijpharm.2004.07.042] [PMID: 15707731]
[180]
Hirakawa Y, Ueda H, Miyano T, Kamiya N, Goto M. New insight into transdermal drug delivery with supersaturated formulation based on co-amorphous system. Int J Pharm 2019; 569118582.
[http://dx.doi.org/10.1016/j.ijpharm.2019.118582] [PMID: 31381987]
[181]
Shayanfar A, Ghavimi H, Hamishekar H, Jouyban A. Coamorphous atorvastatin calcium to improve its physicochemical and pharmacokinetic properties. J Pharm Pharm Sci 2013; 16(4): 577-87.
[http://dx.doi.org/10.18433/J3XS4S] [PMID: 24210065]
[182]
Qian S, Heng W, Wei Y, Zhang J, Gao Y. Coamorphous lurasidone hydrochloride–saccharin with charge-assisted hydrogen bonding interaction shows improved physical stability and enhanced dissolution with pH-independent solubility behavior. Cryst Growth Des 2015; 15(6): 2920-8.
[http://dx.doi.org/10.1021/acs.cgd.5b00349]
[183]
Wu W, Löbmann K, Schnitzkewitz J, et al. Aspartame as a co-former in co-amorphous systems. Int J Pharm 2018; 549(1-2): 380-7.
[http://dx.doi.org/10.1016/j.ijpharm.2018.07.063] [PMID: 30075253]
[184]
Bohr A, Nascimento TL, Harmankaya N, et al. Efflux inhibitor Bicalutamide increases oral bioavailability of the poorly soluble efflux substrate docetaxel in co-amorphous anti-cancer combination therapy. Molecules 2019; 24(2): 266.
[http://dx.doi.org/10.3390/molecules24020266] [PMID: 30642009]
[185]
Gao Y, Liao J, Qi X, Zhang J. Coamorphous repaglinide–saccharin with enhanced dissolution. Int J Pharm 2013; 450(1-2): 290-5.
[http://dx.doi.org/10.1016/j.ijpharm.2013.04.032] [PMID: 23612357]
[186]
Beyer A, Radi L, Grohganz H, Löbmann K, Rades T, Leopold CS. Preparation and recrystallization behavior of spray-dried co-amorphous naproxen–indomethacin. Eur J Pharm Biopharm 2016; 104: 72-81.
[http://dx.doi.org/10.1016/j.ejpb.2016.04.019] [PMID: 27130786]
[187]
Haneef J, Chadha R. Drug-drug multicomponent solid forms: Cocrystal, coamorphous and eutectic of three poorly soluble antihypertensive drugs using mechanochemical approach. AAPS PharmSciTech 2017; 18(6): 2279-90.
[http://dx.doi.org/10.1208/s12249-016-0701-1] [PMID: 28101724]
[188]
Hirakawa Y, Ueda H, Wakabayashi R, Kamiya N, Goto M. A novel binary supercooled liquid formulation for transdermal drug delivery. Biol Pharm Bull 2020; 43(3): 393-8.
[http://dx.doi.org/10.1248/bpb.b19-00642] [PMID: 31801924]
[189]
Wairkar S, Gaud R. Co-amorphous combination of nateglinide-metformin hydrochloride for dissolution enhancement. AAPS PharmSciTech 2016; 17(3): 673-81.
[http://dx.doi.org/10.1208/s12249-015-0371-4] [PMID: 26314243]
[190]
Leng D, Kissi EO, Löbmann K, et al. Design of inhalable solid dosage forms of budesonide and theophylline for pulmonary combination therapy. AAPS PharmSciTech 2019; 20(3): 137.
[http://dx.doi.org/10.1208/s12249-019-1344-9] [PMID: 30847607]
[191]
Pang W, Lv J, Du S, Wang J, Wang J, Zeng Y. Preparation of curcumin–piperazine coamorphous phase and fluorescence spectroscopic and density functional theory simulation studies on the interaction with bovine serum albumin. Mol Pharm 2017; 14(9): 3013-24.
[http://dx.doi.org/10.1021/acs.molpharmaceut.7b00217] [PMID: 28703594]
[192]
Sormunen H, Ruponen M, Laitinen R. The effect of co-amorphization of glibenclamide on its dissolution properties and permeability through an MDCKII-MDR1 cell layer. Int J Pharm 2019; 570118653.
[http://dx.doi.org/10.1016/j.ijpharm.2019.118653] [PMID: 31472218]
[193]
Bitay E, Gergely AL, Balint I, et al. Preparation and characterization of lapatinib-loaded PVP nanofiber amorphous solid dispersion by electrospinning. Express Polym Lett 2021; 15(11): 1041-50.
[http://dx.doi.org/10.3144/expresspolymlett.2021.84]
[194]
Mallya P, Yarlagadda DL, Lewis S. A novel stability-indicating RP-HPLC method for the simultaneous estimation and in vitro and in vivo evaluation: Curcumin and Naringin co-amorphous system. Food Anal Methods 2024; 17(5): 751-65.
[http://dx.doi.org/10.1007/s12161-024-02606-9]
[195]
Chishti NAH, Pathan IB, Dehghan MHG, Bairagi SM. Design and development of immediate release pellets formulation containing co amorphous mixture of Aceclofenac: In-vitro and in-vivo study. J Pharm Innov 2024; 19(2): 13.
[http://dx.doi.org/10.1007/s12247-024-09823-z]
[196]
Nair AR, Vullendula SKA, Yarlagadda DL, Bheemisetty B, Dengale SJ, Bhat K. Physicochemical interaction of rifampicin and ritonavir-lopinavir solid dispersion: an in-vitro and ex-vivo investigation. Drug Dev Ind Pharm 2024; 50(3): 192-205.
[http://dx.doi.org/10.1080/03639045.2024.2309508] [PMID: 38305806]
[197]
Yun TS, Jung M, Bang KH, et al. An economically advantageous amorphous solid dispersion of the fixed combination of lopinavir and ritonavir. J Pharm Investig 2023; 53(4): 549-61.
[http://dx.doi.org/10.1007/s40005-023-00623-0]
[198]
Yarlagadda DL, Anand VSK, Nair AR, et al. A computational-based approach to fabricate ceritinib co-amorphous system using a novel co-former Rutin for bioavailability enhancement. Eur J Pharm Biopharm 2023; 190: 220-30.
[http://dx.doi.org/10.1016/j.ejpb.2023.07.019] [PMID: 37524214]
[199]
Chen J, Li H, Li X, et al. Co-amorphous systems using epigallocatechin-3-gallate as a co-former: Stability, in vitro dissolution, in vivo bioavailability and underlying molecular mechanisms. Eur J Pharm Biopharm 2022; 178: 82-93.
[http://dx.doi.org/10.1016/j.ejpb.2022.08.001] [PMID: 35932965]
[200]
Shi X, Song S, Ding Z, Fan B, Huang W, Xu T. Improving the solubility, dissolution, and bioavailability of Ibrutinib by preparing it in a coamorphous state with saccharin. J Pharm Sci 2019; 108(9): 3020-8.
[http://dx.doi.org/10.1016/j.xphs.2019.04.031] [PMID: 31067482]
[201]
Li YW, Zhang HM, Cui BJ, et al. “Felodipine-indomethacin” co-amorphous supersaturating drug delivery systems: “Spring-parachute” process, stability, in vivo bioavailability, and underlying molecular mechanisms. Eur J Pharm Biopharm 2021; 166: 111-25.
[http://dx.doi.org/10.1016/j.ejpb.2021.05.030] [PMID: 34119671]
[202]
Nair A, Varma R, Gourishetti K, Bhat K, Dengale S. Influence of preparation methods on physicochemical and pharmacokinetic properties of co-amorphous formulations: The case of co-amorphous Atorvastatin: Naringin. J Pharm Innov 2020; 15(3): 365-79.
[http://dx.doi.org/10.1007/s12247-019-09381-9]
[203]
Yu D, Kan Z, Shan F, Zang J, Zhou J. Triple strategies to improve oral bioavailability by fabricating coamorphous forms of ursolic acid with piperine: Enhancing water-solubility, permeability, and inhibiting cytochrome P450 Isozymes. Mol Pharm 2020; 17(12): 4443-62.
[http://dx.doi.org/10.1021/acs.molpharmaceut.0c00443] [PMID: 32926628]
[204]
Wei Y, Zhou S, Hao T, Zhang J, Gao Y, Qian S. Further enhanced dissolution and oral bioavailability of docetaxel by coamorphization with a natural P-gp inhibitor myricetin. Eur J Pharm Sci 2019; 129: 21-30.
[http://dx.doi.org/10.1016/j.ejps.2018.12.016] [PMID: 30590119]
[205]
Bahetibieke S, Moinuddin SM, Baiyisaiti A, et al. Co-amorphous formation of Simvastatin-Ezetimibe: Enhanced physical stability, bioavailability and cholesterol-lowering effects in LDLr−/−Mice. Pharmaceutics 2022; 14(6): 1258.
[http://dx.doi.org/10.3390/pharmaceutics14061258] [PMID: 35745830]
[206]
Qiu C, Zhang Y, Fan Y, et al. Solid dispersions of genistein via solvent rotary evaporation for improving solubility, bioavailability, and amelioration effect in HFD-induced obesity mice. Pharmaceutics 2024; 16(3): 306.
[http://dx.doi.org/10.3390/pharmaceutics16030306] [PMID: 38543200]
[207]
Wang X, Cao J, Li Z, et al. Co-amorphous mixture of erlotinib hydrochloride and gallic acid for enhanced antitumor effects. J Drug Deliv Sci Technol 2024; 91105200.
[http://dx.doi.org/10.1016/j.jddst.2023.105200]
[208]
Nascimento ALCS, Martins ICB, Spósito L, et al. Indomethacin-omeprazole as therapeutic hybrids? Salt and co-amorphous systems enhancing physicochemical and pharmacological properties. Int J Pharm 2024; 653123857.
[http://dx.doi.org/10.1016/j.ijpharm.2024.123857] [PMID: 38281693]
[209]
Mohamed EM, Dharani S, Nutan MTH, et al. Application of sucrose acetate isobutyrate in development of co-amorphous formulations of tacrolimus for bioavailability enhancement. Pharmaceutics 2023; 15(5): 1442.
[http://dx.doi.org/10.3390/pharmaceutics15051442] [PMID: 37242683]
[210]
Li B, Hu Y, Wu T, et al. Apigenin-oxymatrine binary coamorphous mixture: Enhanced solubility, bioavailability, and antiinflammatory effect. Food Chem 2022; 373(Pt B): 131485.
[http://dx.doi.org/10.1016/j.foodchem.2021.131485] [PMID: 34740050]

Rights & Permissions Print Cite
Article Metrics
24
3
Wayfinder Image
© 2026 Bentham Science Publishers | Privacy Policy